Naltrexone ER/bupropion ER: A review in obesity management

Drugs

Volumn 75, Issue 11, 2015, Pages 1269-1280

  Greig, Sarah L ^a   Keating, Gillian M ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; CARBAMAZEPINE; FLUVOXAMINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LEVODOPA; LORCASERIN; MELANOCORTIN; METFORMIN; NALTREXONE; NELFINAVIR; NORFLUOXETINE; ORAL ANTIDIABETIC AGENT; PAROXETINE; PHENOBARBITAL; PHENTERMINE; PHENYTOIN; PLACEBO; SERTRALINE; TICLOPIDINE; ANTIOBESITY AGENT; BUPROPION HYDROCHLORIDE, NALTREXONE HYDROCHORIDE DRUG COMBINATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ARTICLE; BODY WEIGHT; CARDIOMETABOLIC RISK; CHOLECYSTITIS; CONSTIPATION; DEPRESSION; DIET RESTRICTION; DIET THERAPY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; SUICIDAL IDEATION; TINNITUS; TREMOR; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ADULT; ANIMAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; OVERWEIGHT;

ADULT; ANIMALS; ANTI-OBESITY AGENTS; BUPROPION; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; NALTREXONE; OBESITY; OVERWEIGHT;

EID: 84938196283     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0427-5     Document Type: Article

References (32)

1. World Health Organization. Obesity and overweight: fact sheet no. 311. 2015. http://www.who.int/mediacentre/factsheets. Accessed 8 June 2015.
2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-62.
4. National Institute for Health and Care Excellence. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. NICE clinical guideline 189. 2014. http://www.nice.org.uk/guidance. Accessed 8 June 2015.
5. Takeda Pharmaceuticals America Inc. Contrave® (naltrexone HCl and bupropion HCl) extended-release tablets: US prescribing information. 2014. http://www.fda.gov. Accessed 8 June 2015.
6. Orexigen Therapeutics Ireland Ltd. MysimbaTM 8 mg/90 mg prolonged-release tablets: EU summary of product characteristics. 2015. http://www.ema.europe.eu. Accessed 8 June 2015.
7. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11.
8. Sinnayah P, Wallingford N, Evans A, et al. Bupropion and naltrexone interact synergistically to decrease food intake in mice [abstract no. 567-P]. Obesity. 2007;15(Suppl.):A179.
9. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17(1):30-9.
10. Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898-906.
11. Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013;15(9):863-6.
12. Wang GJ, Tomasi D, Volkow ND, et al. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int J Obes. 2014;38(5):682-8.
13. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
14. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935-43.
15. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19(1):110-20.
16. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-9.
17. Plutzky J, Chilton R, Still C, et al. Weight loss, blood pressure, pulse and circadian patterns with naltrexone sustained-release/ bupropion sustained-release combination therapy for obesity [abstract no. 1013-286]. J Am Coll Cardiol. 2011;57(14 Suppl):E517.
18. GlaxoSmithKline. Zyban® (bupropion hydrochloride) sustainedrelease tablets, for oral use: US prescribing information. 2014. http://www.fda.gov. Accessed 8 June 2015.
19. Duramed Pharmaceuticals Inc. Revia® (naltrexone hydrochloride tablets USP) 50 mg: US prescribing information. 2013. http://www.fda.gov. Accessed 8 June 2015.
20. Kolotkin RL, Burns C, Walsh B, et al. Combination naltrexone/bupropion therapy resulted in clinically meaningful improvements in weight and quality of life (QoL): integrated analysis of four phase 3 trials [abstract no. 1056-P]. Diabetes. 2013;62(Suppl 1):A272.
21. Apovian C, Burns C, Walsh B, et al. An integrated analysis of weight loss with combination naltrexone/bupropion therapy by BMI (obesity) classification [abstract no. 1130-P]. Diabetes. 2013;62(Suppl 1):A293-4.
22. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153-60.
23. Fujioka K, Walsh B, Burns C, et al. Early improvement in control of eating is associated with long-term weight loss-integrated analysis of four phase 3 trials of combination naltrexone/bupropion treatment [abstract no. 1149-P]. Diabetes. 2013;62(Suppl. 1):A299.
24. Foreyt JP, Hill J, Maier H, et al. Naltrexone SR/bupropion SRinduced weight loss is independent of nausea [abstract no. 218-P]. Obesity. 2009;17(Suppl. 2):S109-10.
25. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142-52.
26. Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922-33.
27. Cunningham JW, Wiviott SD. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol. 2014;37(11):693-9.
28. Orexigen Therapeutics Inc. Orexigen announces successful interim analysis of Contrave Light Study: company will resubmit the Contrave NDA in the next few weeks-potential approval by June 2014 [media release]. 25 Nov 2013. http://www.orexigen.com.
29. US Food and Drug Administration. Contrave (application number 200063Orig1s000): summary review. 2014. http://www.fda.gov. Accessed 8 June 2015.
30. Orexigen Therapeutics Inc. Takeda Pharmaceuticals and Orexigen Therapeutics announce termination of the cardiovascular outcomes study (Light Study) of the obesity drug Contrave® (naltrexone HCl and bupropion HCl) [media release]. 12 May 2015. http://orexigen.com.
31. McElroy SL, Guerdjikova AI, Kim DD, et al. Naltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord. 2013. doi:10.4088/PCC.12m01494.
32. Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/ bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014;13(6):831-41.